Item 7.01. Regulation FD Disclosure.

On January 13, 2020, Deciphera Pharmaceuticals, Inc., or the Company, issued the press release attached hereto as Exhibit 99.1. In addition, spokespersons of the Company plan to present the information in the presentation slides attached hereto as Exhibit 99.2.

The furnishing of the attached press release and presentation is not an admission as to the materiality of any information therein. The information contained in the press release and presentation is summary information that is intended to be considered in the context of more complete information included in the Company's filings with the U.S. Securities and Exchange Commission, or the SEC, and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the "Cautionary Note Regarding Forward-Looking Statements" section of the press release in Exhibit 99.1 attached hereto and the "Forward-Looking Statements" section of the presentation in Exhibit 99.2 attached hereto.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report and the presentation attached as Exhibit 99.2 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



                Exhibit
                  No.     Description

                99.1        Press release, furnished herewith.

                99.2        Presentation, furnished herewith.




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses